Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 37Genitourinary 9Gynecologic 7Gastrointestinal 6Endocrine 6Head & Neck 5Other solid neoplasm 4Sarcoma 3NET 3Breast 3Lymphoid 2Dermatologic 2CNS 2

Conditions

Brain Neoplasms 1905Glioblastoma 1797Glioma 1130Central Nervous System Neoplasms 599Astrocytoma 594Neuroblastoma 552Gliosarcoma 465Oligodendroglioma 364Neoplasms 312Breast Neoplasms 273Medulloblastoma 272Carcinoma, Non-Small-Cell Lung 227Recurrence 199Sarcoma 184Neoplasm Metastasis 183Melanoma 182Meningioma 177Ependymoma 176Lung Neoplasms 157Lymphoma 134Osteosarcoma 127Meningeal Carcinomatosis 126Neurofibromatosis 1 114Wilms Tumor 111Ovarian Neoplasms 110Diffuse Intrinsic Pontine Glioma 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Rhabdomyosarcoma 101Lymphoma, Non-Hodgkin 96Burkitt Lymphoma 89

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Small Cell × CNS × Clear all
NCT05500391 2026-03-18

SUR-CAN

Centre Oscar Lambret

Phase 2 Recruiting
88 enrolled
CNSEndocrineGastrointestinalNETSarcoma

Carcinosarcoma, Glioma, Seminoma, Adenocarcinoma, Clear Cell, Carcinoma, Small Cell, Sex Cord-Gonadal Stromal Tumors, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
157 enrolled 26 charts
CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡